Thymalin,
the immune and longevity peptide.
Thymalin is a polypeptide complex extracted from the thymus gland of young calves, originally developed at the USSR Institute of Gerontology in the 1970s and approved for medical use in Russia since the 1980s. Thymalin peptide restores immune competence by stimulating T-lymphocyte differentiation, modulating natural killer cell activity, and correcting age-related immune decline — the progressive collapse of thymic function known as thymic involution. In the longest human clinical trial ever conducted on a therapeutic peptide, thymalin reduced cardiovascular mortality by 45% and all-cause mortality by 28% over a 6-year follow-up period in elderly patients. This guide covers everything known about thymalin: mechanism of action, dosage protocols, clinical evidence, side effects, how thymalin peptide compares to epithalon and thymosin alpha-1, and why the thymus is the most important gland in the longevity conversation.
Thymalin restores the immune system from the thymus down.
The thymus gland is the master regulator of adaptive immunity. It is where T-cell progenitors from the bone marrow mature into functional T-lymphocytes — the cells responsible for identifying and destroying infected cells, coordinating immune responses, and maintaining immunological memory. The problem is that the thymus begins shrinking after puberty. By age 50, thymic tissue is largely replaced by fat. By age 70, functional thymic output has declined by over 95%. This process — thymic involution — is the single largest driver of age-related immune decline, and it is why older adults are more susceptible to infections, cancers, and chronic inflammatory disease.
Thymalin peptide intervenes directly at this bottleneck. The polypeptide complex contains short peptides (2–8 amino acids) that regulate gene expression in thymic epithelial cells, stimulating the differentiation and maturation of T-cell progenitors into functional CD4+ and CD8+ T-lymphocytes. The result is a measurable increase in T-cell count, a restoration of the CD4/CD8 ratio toward youthful norms, and an upregulation of natural killer (NK) cell activity. Unlike synthetic immunostimulants that push the immune system into overdrive, thymalin peptide acts as an immunomodulator — it normalizes immune function, correcting both immunodeficiency and the overactivation seen in autoimmune conditions and chronic inflammation.
The downstream effects extend beyond immunity. Thymalin regulates the expression of gerontogenes — genes directly associated with aging — and modulates cytokine balance, heat-shock protein synthesis, and fibrinolytic activity. This is why thymalin peptide shows benefits across cardiovascular health, neurological function, and metabolic regulation in addition to its primary immunomodulatory effects. For a complete breakdown of clinical applications, see the thymalin benefits guide.
Thymalin peptide, covered in depth.
Dosage protocols, clinical evidence, side effects, longevity data, and comparisons to epithalon, thymosin alpha-1, and thymogen.
Thymalin dosage
Standard 5–10 mg daily protocol, cycle length, reconstitution, injection technique, and the clinical dosing regimens from 40 years of Russian and Eastern European medical use.
Read the thymalin dosage guide → 02 / 05Thymalin benefits
Immune restoration, T-cell differentiation, cardiovascular mortality reduction, anti-aging, anti-inflammatory effects, hair follicle support, and the 6-year longevity trial data.
Read the thymalin benefits guide → 03 / 05Thymalin side effects
Safety profile from 40+ years of clinical use, reported adverse effects, contraindications, zinc dependency, and pregnancy considerations.
Read the thymalin safety guide → 04 / 05Thymalin vs epithalon
Thymic immunomodulation versus pineal telomere biology, the Khavinson longevity protocol that combines both, and which peptide to prioritize for anti-aging.
Read the comparison → 05 / 05Thymalin vs thymosin alpha-1
Polypeptide complex versus single-sequence synthetic, FDA approval status, clinical applications in hepatitis and cancer, and how thymalin compares to thymulin and thymogen.
Read the comparison →Thymalin clinical data at a glance.
| Study | Population | Protocol | Duration | Primary outcome |
|---|---|---|---|---|
| Khavinson & Morozov (2003) | 266 elderly patients (60+) | Thymalin + epithalon, annual cycles | 6 years | -28% all-cause mortality; -45% cardiovascular mortality |
| Khavinson et al. (2020) | Severe COVID-19 patients | Thymalin adjunct therapy | Acute phase | Suppressed cytokine storm gene expression, reduced hyperinflammatory response |
| Anisimov & Khavinson (2010) | Review of 35+ years clinical use | Various thymalin protocols | Meta-analysis | Restored T/B lymphocyte ratios, normalized immune parameters across disease states |
| Kuznik et al. (2011) | Pneumonia patients | Thymalin + thymogen | Treatment course | Normalized coagulation and fibrinolytic activity of blood plasma proteins |
The clinical evidence for thymalin peptide spans over four decades and hundreds of published studies, predominantly from Russian and Eastern European research institutions. The landmark study — the Khavinson & Morozov 6-year trial — remains the longest human clinical trial ever conducted on a peptide bioregulator and produced the most significant mortality reduction data in the peptide literature. Subsequent studies during the COVID-19 pandemic validated thymalin's mechanism in acute immune crisis, demonstrating measurable suppression of the cytokine storm responsible for severe outcomes. For a full breakdown of benefits across immune, cardiovascular, neurological, and anti-aging applications, see the thymalin benefits guide.
Thymalin FAQ.
What is thymalin?
Thymalin is a polypeptide complex extracted from the thymus gland of young calves, containing short peptides (2–8 amino acids) that regulate immune function, T-cell differentiation, and gene expression related to aging. Developed in the Soviet Union in the 1970s by researchers Vladimir Khavinson and Vyacheslav Morozov, thymalin peptide has been approved for medical use in Russia since the 1980s and has accumulated over 40 years of clinical data across immune restoration, anti-aging, and infection management. Thymalin belongs to a class of compounds called cytomedins — peptide bioregulators that influence DNA transcription and cellular differentiation at the genetic level.
What does thymalin do?
Thymalin peptide restores immune competence by stimulating the thymus gland to produce functional T-lymphocytes — the adaptive immune cells that decline dramatically with age due to thymic involution. Specifically, thymalin enhances T-cell differentiation and maturation, increases the CD4/CD8 T-cell ratio, modulates natural killer cell activity, regulates cytokine balance, and supports the expression of genes associated with immune function and longevity. The clinical result is improved resistance to infections, reduced chronic inflammation, and — in the landmark 6-year trial — significant reductions in cardiovascular and all-cause mortality in elderly patients.
How is thymalin different from other thymic peptides?
Thymalin is a multi-peptide complex containing several active short peptides, whereas thymosin alpha-1 (thymalfasin) and thymulin are single-sequence peptides with more targeted mechanisms. This gives thymalin broader biological activity — it influences multiple immune pathways simultaneously rather than targeting a single receptor or cell type. Thymosin alpha-1 is FDA-approved in some countries and has stronger Western clinical data, particularly in hepatitis and oncology. Thymulin is a zinc-dependent nonapeptide focused on T-cell maturation. Thymogen is a dipeptide (EW) isolated from thymalin itself, making it essentially one active component of the larger thymalin complex. See the thymalin vs thymosin alpha-1 comparison for a detailed analysis.
Is thymalin FDA-approved?
Thymalin is not FDA-approved in the United States. It is approved and widely used in Russia and several Eastern European countries for immune modulation, anti-aging therapy, and post-illness recovery. In the US, thymalin peptide is available as a research compound and through specialized compounding sources. The lack of FDA approval reflects the geographic origin of the clinical data rather than a safety concern — thymalin has an extensive safety record spanning over 40 years of documented clinical use with minimal reported adverse effects.
Can thymalin be stacked with epithalon?
Yes. The thymalin and epithalon combination is the most studied peptide stack in the longevity literature. The Khavinson & Morozov 6-year trial used thymalin (thymic immunomodulator) alongside epithalon (pineal telomere peptide) and produced the most significant mortality reduction data in peptide research — 28% reduction in all-cause mortality and 45% reduction in cardiovascular mortality. The two peptides target different systems (immune via thymus vs. endocrine/telomere via pineal gland) and are considered complementary rather than redundant. See the thymalin vs epithalon guide for the full stack protocol.
What is the standard thymalin dosage?
The standard thymalin dosage is 5–10 mg administered daily by subcutaneous or intramuscular injection for 5–10 consecutive days, constituting one cycle. Cycles are typically repeated 2–4 times per year depending on the clinical goal. Preventive protocols use 1–10 mg for 3–5 days. This dosing regimen is derived from decades of clinical use in Russia and Eastern Europe. The short-cycle design reflects thymalin's mechanism — it triggers a cascade of immune restoration that persists for weeks to months after the administration period ends. See the thymalin dosage guide for complete protocol information.